Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Codexis, Inc. (CDXS)

NMS · Biotechnology

$1.50-0.05 (-3.23%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$161.3M
P/E (TTM)
EPS
$-0.34
Div Yield
52W Range
$0.96–$3.87
Beta
2.50

Company overview

Next earnings: 2026-08-11(14d)

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Peers in Biotechnology

All in industry →

Recent press releases

Codexis, Inc. has not issued a press release in this window.

SEC filings

All filings →

Codexis, Inc. has not filed an SEC document in this window.

Codexis, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
6,789,738 sh-46.9%
7,395,740 sh+3.5%
3,135,192 sh-22.9%
3,846,411 sh-3.8%
4,941,542 sh+5.8%
3,990,169 sh-1.0%
abrdn plc$13.0M
7,966,498 sh+94.7%

People at Codexis, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$1.5M
NI -$20.7M
06/25
$2.4M
NI -$13.3M
09/25
$8.6M
NI -$19.6M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.22
Prior: $-0.16
Revenue sparkline